Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its …
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss …
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances Read More
WILMINGTON, DE — AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer (MIBC), making it the first perioperative immunotherapy available in the U.S. …
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer Read More
CHEYNEY, PA — Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) development to target cancers that overexpress the humoral immunosuppressive oncology (HIO) factor ICAM-1. The …
Navrogen Advances Antibody Technology to Combat Cancer with New Findings Read More
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
SPRING HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to …
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study Read More
PHILADELPHIA, PA— Researchers at The Wistar Institute, led by Jessie Villanueva, Ph.D., have made significant strides in combating treatment-resistant melanoma. Their latest discovery focuses on inhibiting the gene S6K2, a breakthrough …
Wistar Institute Uncovers New Strategy for Treating Resistant Melanoma Read More
SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, …
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development Read More WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More